Visiopharm Glint Lab Collaboration
Glint Lab, a San Diego based digital pathology laboratory, is excited to announce a strategic partnership with Visiopharm, a global leader in AI-driven precision pathology. This collaboration with Visiopharm’s Oncotopix Discovery platform elevates our end-to-end services, reinforcing our commitment to quality and transparency in scientific research.
At Glint Lab, our goal is to turn pathology data into actionable insights, empowering early-stage discovery. This collaboration provides our scientists and clients with best-in-class image analysis and data exploration tools. A key factor in selecting Visiopharm was its unique data exploration capabilities, designed to bridge the gap between quantitative data extracted from the samples and the tissue images. These features allow researchers to connect their findings from quantitative data to spatial insights in the tissue, enabling them to verify hypotheses and gain a deeper understanding of their study.
Digital pathology is a hotbed for developing the next generation of therapies. By integrating Visiopharm’s advanced AI-driven solutions, at Glint Lab, we are better equipped to deliver tailored solutions for unique and novel research questions. Additionally, to enhance our quality control processes, we leverage these AI-based solutions to ensure high precision and reproducibility in the results. This ensures that every step of the pathology workflow at Glint Lab, from tissue analysis to data interpretation, meets the highest standards.
Choosing Visiopharm’s Oncotopix Discovery was a clear decision for us at Glint Lab. Their advanced image analysis platform and unique data exploration tools perfectly align with our mission to deliver high-quality research services and enable our clients to explore tissue-derived data much deeper than they usually would. This partnership will significantly enhance our ability to support our clients’ scientific discoveries.
“Visiopharm is thrilled to strategically collaborate with Glint Lab, a forward-thinking CRO that shares our commitment to quality and innovation. By integrating our Oncotopix Discovery platform, Glint Lab will be able to offer their clients unparalleled precision and insights in tissue-based image analysis,” said Jeni Caldara, Strategic Partnership Manager of Visiopharm.
About Visiopharm
Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no less than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
For more information visit visiopharm.com.
About Glint Lab
Glint Lab is a rising CRO dedicated to delivering high-quality, transparent research services. Specializing in histopathology, Glint Lab offers a comprehensive suite of services including tissue processing, sectioning, histochemical staining, immunohistochemistry, immunofluorescence, whole slide imaging, and quantitative image analysis. By integrating advanced image analysis software, Glint Lab ensures that clients receive the most reliable and insightful data to support their scientific endeavors. Their team of experienced histologists and scientists is committed to collaborating closely with clients from study design to data interpretation, ensuring optimal research outcomes.
For more information, please visit glintlab.com.
